home / stock / meobf / meobf news

MEOBF News and Press, Mesoblast Ltd Ord

Stock Information
Company Name: Mesoblast Ltd Ord
Stock Symbol: MEOBF
Market: OTC
Website: mesoblast.com
Menu
MEOBF MEOBF Quote MEOBF Short MEOBF News MEOBF Articles MEOBF Message Board
Get MEOBF Alerts

News, Short Squeeze, Breakout and More Instantly...
MEOBF - Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....
MEOBF - Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...

MEOBF - Mesoblast Corporate Presentation at Investor Conference

NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Applicati...

MEOBF - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: ȁ...
MEOBF - Mesoblast Limited: Back From The Dead

2024-04-10 13:29:22 ET Summary Mesoblast Limited has been on a major run recently as its cell therapy candidate is back on track towards potential approval. The company has some upcoming potential catalysts in the quarters ahead and is advancing its pipeline on several fronts. ...

MEOBF - United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phas...

MEOBF - Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launch...
MEOBF - Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executi...

MEOBF - United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor ® (re...

MEOBF - Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: ...
Next 10